[A14-11] Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)

Last updated 05.06.2014

Project no.:

Commission awarded on 11.03.2014 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Skin and hair


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


Ipilimumab in advanced melanoma: added benefit for non-pretreated patients still not proven

In two addenda, IQWiG conducted an assessment of study data on further comparator therapy and on updated data analyses

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.